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ABSTRACT
Objective: To evaluate the effectiveness of cervical pessary for preventing spontaneous preterm
birth (SPTB) in twin pregnancies with an asymptomatic transvaginal ultrasound cervical length
(TVU CL) in the second trimester.
Methods: We performed a meta-analysis including all randomized clinical trials (RCTs) comparing
the use of cervical pessary (i.e. intervention group) with expectant management (i.e. control
group). The primary outcome was incidence of SPTB<34 weeks.
Results: Three trials, including 481 twin pregnancies with short cervix, were analyzed. Two RCTs
defined short cervix as TVU CL25mm and one as TVU CL38mm. Pessary was not associated
with prevention of SPTB, and the mean gestational age at delivery and the mean latency were
similar in the pessary group compared to the control group. Moreover, no benefits were noticed
in neonatal outcomes.
Conclusions: Use of the Arabin pessary in twin pregnancies with short TVU CL at 16–24 weeks
does not prevent SPTB or improve perinatal outcome.
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Introduction
Spontaneous preterm birth (SPTB) remains the number
one cause of perinatal mortality in many countries,
including the United States [1]. Multiple gestations are
at increased risk of SPTB [1]. A short cervical length
(CL) on transvaginal ultrasound (TVU) has been shown
to be a good predictor of SPTB, in both singletons and
twins [2].
The cervical pessary is a silicone device that has
been used to prevent SPTB. The efficacy of the cervical
pessary has been assessed in several populations
including singletons with short CL [3], unselected twins
[4,5], twins with short CL [6], and triplet pregnancies
[7]. Several randomized clinical trials (RCTs) have been
published [3–6], and several are ongoing [7–9].
However, no consensus on use of the cervical pessary
in pregnancy or guidelines for management has been
assessed.
The aim of this systematic review was to assess the
effectiveness of the cervical pessary in preventing SPTB
in women with twin gestations with an asymptomatic
short CL in the second trimester.
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Methods
Eligibility criteria
The review protocol was established by two investiga-
tors (G. S. and V. B.) prior to commencement and was
registered with the PROSPERO International
Prospective Register of Systematic Reviews (registra-
tion No. CRD42016035936).
Two authors (G. S. and A. C.) identified trials by
independently searching the electronic databases
MEDLINE, Scopus, ClinicalTrials.gov, the PROSPERO
International Prospective Register of Systematic
Reviews, EMBASE, and the Cochrane Central Register
of Controlled Trials with the use of a combination of
the following text words: “pessary,” “cervical,” “cervix,”
“cervical length,” “preterm birth,” “twins,” “randomized
trial,” “preterm delivery,” “prematurity” “clinical,” and
“insufficiency” from inception of each database until
February 2016. Agreement regarding potential rele-
vance was reached by discussion with a third reviewer
(S. X.).
Study selection
We included all RCTs comparing the use of cervical
pessary (i.e. intervention group) with expectant man-
agement (i.e. control group) for prevention of SPTB in
twin pregnancies with short CL. Trials on singleton
gestations and higher-order multiples other than twin
gestations were excluded. Quasi-randomized trials (i.e.
trials in which allocation was done on the basis of a
pseudo-random sequence, e.g. odd/even hospital
number or date of birth, alternation) were also
excluded.
Risk of bias
The risk of bias in each included study was assessed
using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions [10]. Seven
domains related to risk of bias were assessed in each
included trial since there is evidence that these issues
are associated with biased estimates of treatment
effect: (1) random sequence generation; (2) allocation
concealment; (3) blinding of participants and person-
nel; (4) blinding of outcome assessment; (5) incomplete
outcome data; (6) selective reporting; and (7) other
bias. Review authors’ judgments were categorized as
“low risk,” “high risk,” or “unclear risk” of bias [10].
Two authors (G. S. and A. C.) independently
assessed inclusion criteria, risk of bias, and data extrac-
tion. Disagreements were resolved by consensus
through discussion. Data from each eligible study
were extracted without modification of original data
onto custom-made data collection forms. Differences
were reviewed, and further resolved by common
review of the entire process.
Data extraction
Primary and secondary outcomes were defined before
data extraction. The primary outcome was incidence of
SPTB<34 weeks. The secondary outcomes were
SPTB<37,<32, and<28 weeks, PTB <37, <34, <32,
and <28 weeks,mean gestational age (GA) at delivery
(in weeks), mean latency (i.e. time from randomization
to delivery) (in days), and neonatal outcomes, includ-
ing incidence of low birth weight (LBW) (i.e. BW<2500
grams), incidence of very LBW (VLBW) (i.e. BW<1500
grams), necrotizing enterocolitis (NEC), sepsis, respira-
tory distress syndrome (RDS), intraventricular hemor-
rhage (IVH) (grade 3 or 4), admission to neonatal
intensive care unit (NICU), fetal mortality (i.e. fetal
death after 20 weeks), neonatal mortality (i.e. death of
a live-born baby within the first 28 days of life), and
perinatal death (i.e. either fetal mortality or neonatal
mortality).
We planned to assess the primary outcome (i.e. inci-
dence of SPTB<34 weeks) in subgroup analyses classi-
fying whole trials by interaction test as described by
Cochrane Handbook for Systematic Review of
Interventions.10 The subgroup analyses entailed: twins
with prior SPTB; twins without prior SPTB; TVU CL
25mm; and TVU CL 20mm.
Data analysis
The data analysis was completed independently by
two authors (G. S. and S. X.) using Review Manager 5.3
(Copenhagen: The Nordic Cochrane Centre, Cochrane
Collaboration, 2014) [10]. The completed analyses
were then compared, and any difference was resolved
with review of the entire data and independent ana-
lysis. Between-study heterogeneity was explored using
the I2 statistic, which represents the percentage of
between-study variation that is due to heterogeneity
rather than chance. A value of 0% indicates no
observed heterogeneity, whereas I2 values of 50%
indicate a substantial level of heterogeneity. A fixed
effects model was used if substantial statistical hetero-
geneity was not present. On the contrary, if there was
evidence of significant heterogeneity between studies
included, a random effect model was used [10].
Potential publication biases were assessed statistic-
ally by using Begg’s and Egger’s tests [10]. p values
<0.05 was considered statistically significant. Tests for
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funnel plot asymmetry were carried out only with an
exploratory aim when the total number of publications
included for each outcome was less than 10. In this
case, the power of the tests is too low to distinguish
chance from real asymmetry.
The summary measures were reported as relative
risk (RR) or as mean differences (MD) with 95% confi-
dence interval (CI).
The meta-analysis was reported following the
Preferred Reporting Item for Systematic Reviews and
Meta-analyses (PRISMA) statement [11].
Results
Study selection and study characteristics
Figure 1 shows the flow diagram (PRISMA template) of
information through the different phases of the review.
Five RCTs were assessed for eligibility [3–6,12]. Two trials
were excluded since they enrolled singleton gestations
with a short CL. Three RCTs, which met the inclusion cri-
teria, were included in the meta-analysis [4–6]. Tests for
funnel plot asymmetry were carried out only with an
exploratory aim because the total number of publica-
tions included for each outcome was less than 10.
Despite this, the overall risk of bias of the included trials
was low (Figure 2). All of the included studies had a low
risk of bias in “random sequence generation,” and
“incomplete outcome data.” Adequate methods for allo-
cation of women were used in the three RCTs. Blinding
was considered not feasible methodologically given the
intervention, and none of the included studies were
double-blind. Publication bias, assessed using Begg’s
and Egger’s tests, showed no significant bias (p¼ 0.89
and p¼ 0.73, respectively). One author provided unpub-
lished additional data from his trial [4].
Table 1 shows the characteristics of the included tri-
als. The mean GA at randomization was approximately
21 weeks in both groups (pessary group and control
group). In all three studies, the pessary was removed
by a simple vaginal examination at approximately 37
weeks gestation, or earlier if the women presented
with rupture of membranes, vaginal bleeding, or pain-
ful uterine contractions. Only in Goya et al. the pessary
was not initially removed if preterm rupture of mem-
branes occurred: these women were followed up at
the hospital, and if labor began or chorioamnionitis
was detected, the pessary was removed [6]. However,
only one patient in the pessary group developed
preterm premature rupture of membranes [6]. All
RCTs used the Arabin pessary (Conformite Europeene
marking 0482).
The three trials included twin pregnancies with or
without a prior preterm birth. The Spanish RCT
enrolled only twin pregnancies with a short CL [6],
whereas Nicolaides et al. and Liem et al. enrolled unse-
lected twin pregnancies but performed subgroup anal-
yses in twins with a short CL [4,5]. Only the subsets of
women with a short TVU CL were included in the
meta-analysis. Two RCTs defined a short CL as TVU
CL25mm [4,6], while in the Liem et al.’s trial [5]
short cervix was defined as TVU CL38mm. Women
with major fetal defects, active vaginal bleeding, pla-
centa previa, twin-to-twin transfusion syndrome or
selective fetal growth restriction at the time of the ran-
domization, history of cone biopsy, cervical cerclage
in situ, painful regular uterine contraction, and rup-
tured membranes were excluded [4–6].
Regarding the use of progesterone, Goya et al.
and Liem et al. did not treat patients with
Figure 1. Flow diagram of studies identified in the systematic
review. (Prisma template [preferred reporting item for system-
atic reviews and meta-analyses]). RCTs, randomized clinical
trials.
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progesterone [5,6], while Nicolaides et al. reported
the use of vaginal progesterone in two patients in the
control group [4]. Liem at al. included also 18 women
with triplet pregnancies in the trial [5]. However, only
one, who had short TVU CL, was included in our meta-
analysis.
Synthesis of results
Out of the 481 women with twin pregnancies with a
short TVU CL included in the meta-analysis, 252 (52%)
received the Arabin pessary (i.e. intervention group),
while 229 (48%) did not (i.e. control group). Use of
Arabin pessary in twin gestations with short CL at
16–24 weeks, was not associated with prevention of
SPTB <37, <34 (25.3% vs 31.0%; RR 0.72, 95% CI 0.25
to 2.06; Figure 3), <32 and 28 weeks, compared to no
pessary. Data did not change when indicated PTB
were added. Indeed, use of Arabin pessary did not
reduce the incidence of PTB <37 weeks. A significant
decrease in PTB <32 (RR 0.48, 95% CI 0.24 to 0.96)
and <28 weeks (RR 0.24, 95% CI 0.07 to 0.83) was
noticed, but only one trial [5] was included and there-
fore data could not be meta-analyzed. Data on PTB
Figure 2. Assessment of risk of bias. (A) Summary of risk of bias for each trial; plus sign: low risk of bias; minus sign: high risk of
bias; question mark: unclear risk of bias. (B) Risk of bias graph about each risk of bias item presented as percentages across all
included studies.
Table 1. Descriptive data of the included trials.
Liem et al. [5] Nicolaides et al. [4] Goya et al. [6]
Study location Netherlands Multicenter Spain
Number of centers 40 23 5
Months of study 30 33 42
Sample size 813 (403 vs. 410) 1,180 (590 vs. 590) 134 (68 vs. 66)
GA at randomization (Range) 160–206 200–246 180–226
GA at randomization (mean ± SD, weeks) 16.9 ± 2.0 vs. 17.0 ± 2.0 22.6 ± 3.2 vs. 22.7 ± 2.8 22.6 ± 3.2 vs. 22.7 ± 2.8
Inclusion criteria Unselected multiple pregnancies Unselected twins Twins with short CL
Monochorionic pregnancy 21.6% vs. 24.4% 18.8% vs. 18.8% 19.1% vs. 17.6%
Definition of short CL TVU CL 38mm TVU CL 25mm TVU CL 25mm
Women with short CL at randomization 133/813 (16.4%) 214/1,180 (18.1%) 134/134 (100%)
Prior SPTB 29/403 (7.2%) vs. 26/410 (6.3%) 20/590 (3.4%) vs. 33/590 (5.6%) 11/68 (16.2%) vs. 12/66 (18.2%)
Type of cervical pessary Arabin Arabin Arabin
Primary outcome Composite perinatal outcome SPTB <34 weeks SPTB <34 weeks
Data are presented as total number (number in the pessary group vs. number in the control group.
GA, gestational age; CL, cervical length; TVU, transvaginal ultrasound; SPTB, spontaneous preterm birth.Composite perinatal outcome, defined as at least one of the following: stillbirth, periventricular leucomalacia, severe respiratory distress syndrome, bron-
chopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, proven sepsis, and neonatal death.United Kingdom, Spain, Germany, Austria, Slovenia, Portugal, Italy, Belgium, Albania, China, Brazil and Chile
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<34 were not available (Table 2). The mean GA at
delivery (MD 1.00 week, 95% CI 0.56–2.57) and the
mean latency (MD 9.09 days, 95% CI 1.88–16.30)
were similar in the pessary group compared to the
control group. Regarding neonatal outcomes, no dif-
ferences were found in the incidence of LBW (78.2%
vs. 86.8%; RR 0.87, 95% CI 0.63–1.20), VLBW (21.3% vs.
21.8%; RR 0.97, 95% CI 0.63–1.49), NEC (1.6% vs. 2.2%;
RR 0.73, 95% CI 0.17–3.09), RDS (14.7% vs. 13.0%; RR
1.13, 95% CI 0.70–1.84), IVH (4.8% vs. 5.4%; RR 0.53,
95% CI 0.19–1.42), fetal mortality (3.6% vs. 3.5%; RR
1.02, 95% CI 0.37–2.87), neonatal mortality (3.6% vs.
5.2%; RR 0.68, 95% CI 0.27–1.70), and perinatal death
(7.1% vs. 8.7%; RR 0.62, 95% CI 0.12–3.31) comparing
women in the intervention group with the control
group.
Given that none of the included trials stratified data
by history of SPTB or by different TVU CL cutoffs, per-
forming subgroup analyses were not feasible, except
for TVU CL25mm. Primary outcome of SPTB
<34weeks was similar for singletons with TVU
CL25mm in the pessary vs. no pessary groups:
45/174 (25.9%) vs. 55/174 (31.6%); RR 0.73, 95% CI
0.27–2.01 (Table 2).
Discussion
Main findings
This meta-analysis from three high-quality RCTs,
including 481 twin gestations with short a CL, showed
that the use of a cervical pessary did not prevent SPTB
or improve perinatal outcome. Our meta-analysis
included level 1 data from three appropriately pow-
ered, well-designed RCTs. Pooled data available to
date point to a lack of efficacy of the Arabin pessary
in twin pregnancies with short cervix.
Comparison with existing literature
There is no prior systematic review of the effect of
pessary in multiple gestations with short cervix. A
Cochrane review of one trial, including 385 women,
showed a beneficial effect of cervical pessary in reduc-
ing preterm delivery in singleton gestations with a
short cervix [13]. However, this review included only
singleton gestations with a short CL. Liem et al. pooled
data from six cohort studies, two RCTs, and two
quasi randomized studies showing potential effective-
ness of a cervical pessary in the prevention of preterm
delivery [14].
Strengths and limitations
Our study has several strengths. This meta-analysis
included all studies published to date on the topic,
studies of high quality and with a low risk of
bias according to the Cochrane risk of bias tools.
To our knowledge, no prior meta-analysis on this
issue is as large, up-to-date, or comprehensive.
Key unpublished data were obtained from the ori-
ginal authors [4] (Table 2). The protocol of this
review was a priori registered on PROSPERO.
Statistical tests showed no significant potential publi-
cation biases. Intention-to-treat analysis was used,
and both random and mixed effects models were
used when appropriate. These are key elements
that are needed to evaluate the reliability of a
meta-analysis [10].
Limitations of our study are inherent to the limita-
tions of the included RCTs. Only three trials were
included in the meta-analysis. Although our meta-
analysis represented level-1 data and included
well-designed trials, data from two studies came from
subgroup analyses which were not appropriately pow-
ered for the primary outcome [4,5]. The small number
of studies did not permit meaningful stratified meta-
analyses to explore the test performance in sensitivity
analyses according to the study’s risk of bias or in sub-
group analyses according to the TVU CL cutoffs.
Similarly, since none of the included trials stratified
data by obstetric history, performing subgroup analy-
ses in women with prior SPTB and in women
Figure 3. Forest plot for the risk of spontaneous preterm birth <34 weeks. CI, confidence interval; M-H, Mantel-Haenszel; df,
degrees of freedom.
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without prior SPTB was not feasible. The presence of
co-treatments, slightly different gestational ages at
inclusion, and CL cutoffs represent other limitations of
this systematic review. For example, in the Nicolaides
et al.’s trial, vaginal progesterone was used in two
women in the control group. Nonetheless, even if
these two patients delivered preterm, it would not
have influenced the conclusion of this study or the
meta-analysis. The CL cutoff of 38mm used in the
Liem et al.’s study [5] has not been established as a
risk factor for SPTB in prior studies [15], and is differ-
ent than the 25-mm cutoff used by the other two
included trials [4,6]. Finally, one women with triplet
pregnancy and short TVU CL from the study of Liem
et al. [5] was included in our analysis.
Interpretation
The exact mechanism to explain the efficacy of the
cervical pessary to prevent SPTB in women with a
short CL is not completely clear. Vitsky in 1961 first
suggested that the incompetent cervix is aligned cen-
trally, with no support except the nonresistant vagina
[16]. A lever pessary, therefore, would change the
inclination of the cervical canal, directing it more pos-
teriorly. In doing so, the weight of the pregnancy
would be more on the anterior lower segment [17].
However, the suggestion that some physical interven-
tion, such as a pessary, reduces SPTB by changing the
uterocervical angle has little biological plausibility and
further studies are needed to clarify the mechanism of
action of this device. Another proposed mechanism is
that the pessary could strengthen the immunological
barrier between the chorioamnion-extraovular space
and the vaginal microbiological flora as cerclage has
been postulated to do [3,7–9,18–22].
There are at least five potential reasons why the pes-
sary was effective in the Goya et al. [6] and Liem et al.’s
[5] trials and not in the Nicolaides et al.’s [4] trial. First,
while the training is not specifically described, the
Nicolaides et al.’s [4] study states that the many
research doctors who placed the pessaries did not
receive supervised training and that it was “not possible
to be certain that there was appropriate insertion.”
Goya’s study states that “the central team instructed
the other centers in the use of the pessary.” [6]. This
study reported another mechanism to confirm that the
pessary was placed correctly – all of the patients had a
TVU to confirm correct placement of the pessary [6].
Second, the Nicolaides et al.’s trial [4] included multiple
sites, some of which did not enroll many subjects, rais-
ing the possibility of lesser experience with pessary
placement and management. Of note, there was no
specific training provided regarding pessary insertion in
the Liem et al.’s trial [5] and 40 sites enrolled patients
in the trial. Third, Goya et al. [6] did not remove the
pessaries in patients with ruptured membranes.
Pessaries were removed in patients with ruptured
membranes in the Nicolaides et al. [4] and Liem et al.’s
[5] trials. Fourth, there were more twin pregnancies
with prior SPTB in the Goya et al. [6] (17.2%) and Liem
et al. [5] (6.8%) trials compared to the Nicolaides et al.’s
trial [4] (4.5%). Pessary may be more effective in women
with both prior SPTB and short CL, but this issue could
not be further analyzed given the fact that no prior
SPTB and prior SPTB subgroup analyses were not
reported in any of the trials. Last, the Goya et al. [6] and
Liem et al. [5] trials stratified pessary randomization by
center, while the Nicolaides et al.’s trial [4] did not strat-
ify randomization by center. It is possible that a greater
number of subjects in the Nicolaides et al.’s trial were
randomized to the pessary arm at a site with providers
who did not have significant experience with pessary
insertion. Notably, a recent meta-analysis of six trials
including 1420 singleton pregnancies with TVU
CL25mm showed that the use of cervical pessary
starting at 200–246 weeks does not reduce the rate of
spontaneous preterm delivery or improve perinatal out-
come [23].
Conclusions
Use of the Arabin pessary in twin pregnancies with
short TVU CL at 16–24 weeks may not prevent SPTB or
improve perinatal outcome.
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